Recolonization of Raoul Island by Kermadec red-crowned parakeets Cyanoramphus novaezelandiae cyanurus after eradication of invasive predators, Kermadec Islands archipelago, New Zealand

The Kermadec red-crowned parakeet Cyanoramphus novaezelandiae was driven to extinction on Raoul Island over 150 years ago by introduced cats Felis catus and rats (Rattus norvegicus and R. exulans). These predators were eradicated from the island (2,938 ha) between 2002-04 during the world’s largest multispecies eradication project. In 2008 we documented a unique recolonisation event when parakeets were observed to have returned to Raoul, presumably from a nearby island group, The Herald Islets (51 ha). We captured and aged 100 parakeets, of which 44% were born in 2008, and breeding was observed on Raoul Island. This represents the first evidence of nesting of this species on Raoul Island since 1836. Our findings highlight the global conservation potential for island avifaunas by prioritising eradication areas through consideration of proximity of remnant populations to target management locations, instead of the classical translocation approach alone. The natural recolonization of parakeets on Raoul Island from a satellite source population is to our knowledge, a first for parrot conservation and the first documented population expansion and island recolonization of a parrot species after removal of invasive predators

Unsupervised decoding of long-term, naturalistic human neural recordings with automated video and audio annotations

Fully automated decoding of human activities and intentions from direct neural recordings is a tantalizing challenge in brain-computer interfacing. Most ongoing efforts have focused on training decoders on specific, stereotyped tasks in laboratory settings. Implementing brain-computer interfaces (BCIs) in natural settings requires adaptive strategies and scalable algorithms that require minimal supervision. Here we propose an unsupervised approach to decoding neural states from human brain recordings acquired in a naturalistic context. We demonstrate our approach on continuous long-term electrocorticographic (ECoG) data recorded over many days from the brain surface of subjects in a hospital room, with simultaneous audio and video recordings. We first discovered clusters in high-dimensional ECoG recordings and then annotated coherent clusters using speech and movement labels extracted automatically from audio and video recordings. To our knowledge, this represents the first time techniques from computer vision and speech processing have been used for natural ECoG decoding. Our results show that our unsupervised approach can discover distinct behaviors from ECoG data, including moving, speaking and resting. We verify the accuracy of our approach by comparing to manual annotations. Projecting the discovered cluster centers back onto the brain, this technique opens the door to automated functional brain mapping in natural settings

Exploring the Origin of Sentencing Disparities in the Crown Court: Using Text Mining Techniques to Differentiate between Court and Judge Disparities

Research on sentence consistency in England and Wales has focused on disparities between courts, with differences between judges generally ignored. This is largely due to the limitations in official data. Using text mining techniques from Crown Court sentence records available online we generate a sample of 7,212 violent and sexual offences where both court and judge are captured. Multilevel time-to-event analyses of sentence length demonstrate that most disparities originate at the judge, not the court-level. Two important implications follow: i) the extent of sentencing consistency in England and Wales has been underestimated; and ii) the importance attributed to the location in which sentences are passed – in England and Wales and elsewhere - needs to be revisited. Further analysis of the judge level disparities identifies judicial rotation across courts as a practice conducive of sentence consistency, which suggests that sentencing guidelines could be complemented with other, less intrusive, changes in judicial practice to promote consistency

Caffeinated energy drinks and effects in UK young people

International systematic review evidence indicates an association of caffeinated energy drink use with physical symptoms and lifestyle but is unclear about associations with mental health and behavioural outcomes. The design of studies included in the reviews and the quality of the systematic reviews themselves limits the strength of the conclusions. The lack of UK research in the reviews prompted our analysis of UK population-level data. Our analysis of UK data suggests that many children in the UK consume CEDs with higher consumption reported by older children, by boys, and by those living in northern areas or in more deprived regions. Findings also suggest associations between consumption and physical, psychological, social and educational symptoms, behaviours and wellbeing. A lack of studies that measure these variables over time meant we were unable to determine whether CED consumption is the cause of associated symptoms, behaviours and wellbeing. Future research on this topic should employ longitudinal methods to examine whether CED consumption is responsible for poorer health and wellbeing. Research should also examine the influence of geographic region and deprivation on children’s caffeinated energy drink consumption. The measurement of caffeinated energy drink consumption in the future needs to be consistent across surveys, so that a clearer picture of the frequency, timing and dosage can be established. UK-wide exploration of the context and reasons for caffeinated energy drink consumption is needed and should include examining consumption of CEDs with alcohol in older children aged 16 to 17 years

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists. <br></br> EXPERIMENTAL DESIGN: In this phase I, open-label, dose-escalation study, patients received 35 to 160 mg of dasatinib twice daily in 28-day cycles either every 12 hours for 5 consecutive days followed by 2 nontreatment days every week (5D2) or as continuous, twice-daily (CDD) dosing. <br></br> RESULTS: Sixty-seven patients were treated (5D2, n = 33; CDD, n = 34). The maximum tolerated doses were 120 mg twice daily 5D2 and 70 mg twice daily CDD. DLTs with 160 mg 5D2 were recurrent grade 2 rash, grade 3 lethargy, and one patient with both grade 3 prolonged bleeding time and grade 3 hypocalcemia; DLTs with 120 mg twice daily CDD were grade 3 nausea, grade 3 fatigue, and one patient with both grade 3 rash and grade 2 proteinuria. The most frequent treatment-related toxicities across all doses were nausea, fatigue, lethargy, anorexia, proteinuria, and diarrhea, with infrequent hematologic toxicities. Pharmacokinetic data indicated rapid absorption, dose proportionality, and lack of drug accumulation. Although no objective tumor responses were seen, durable stable disease was observed in 16% of patients.<br></br> CONCLUSION: Dasatinib was well tolerated in this population, with a safety profile similar to that observed previously in leukemia patients, although with much less hematologic toxicity. Limited, although encouraging, preliminary evidence of clinical activity was observed. Doses of 120 mg twice daily (5D2) or 70 mg twice daily (CDD) are recommended for further studies in patients with solid tumors.<br></br&gt